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on	 CD8	 and	 CD4	 T	 cells	 that	 recognise	 tumor-associated	 peptide	 antigens	 (Ag)	 presented	 by	
polymorphic	 major	 histocompatibility	 complex	 (MHC)	 class	 I	 and	 MHC	 class	 II	 molecules,	
respectively.	However,	unconventional	T	cells,	which	 interact	with	MHC	class	 Ib	and	MHC-I	 like	
molecules,	 are	 also	 implicated	 in	 tumor	 immunity,	 although	 their	 role	 here	 is	 unclear.	 These	
include	 unconventional	 T	 cells	 targeting	MHC	 class	 Ib	molecules	 such	 as	 HLA-E	 and	 its	murine	




I-like	 molecules,	 CD1	 molecules	 and	 butyrophylins.	 Considering	 that	 unconventional	 T	 cells	
frequently	 have	 repeated	 and	 predictable	 patterns	 of	 T	 cell	 receptor	 gene	 usage	 in	 unrelated	






T	 lymphocytes	 are	 a	 key	 component	 of	 the	 immune	 system	 and	 a	 major	 focus	 for	 cancer	
immunotherapy.	 The	 vast	 majority	 of	 studies	 into	 the	 immunotherapeutic	 potential	 of	 T	
lymphocytes	have	 focussed	on	conventional	CD8	T	cells	 that	 recognise	peptide	Ags	presented	by	
MHC	 class	 I	 molecules.	 Following	 activation,	 clonal	 expansion	 and	 differentiation,	 these	 cells	
become	 cytotoxic	 T	 lymphocytes	 (CTL)	 with	 the	 ability	 to	 target	 and	 kill	 tumor	 cells	 when	 they	
encounter	specific	tumor	peptide-MHC	class	I	complexes.	These	responses	can	also	be	enhanced	by	
engagement	 of	 CD4	 T	 cell	 help	 against	MHC	 class	 II	 restricted	 tumor	 peptide	 Ags	 (Coulie	 et	 al.,	
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can	 be	 presented	 by	 the	 patient’s	 HLA	 type.	 Further,	 the	 polymorphic	 nature	 of	 the	MHC	 often	
infers	 a	 diverse	 responding	 T	 cell	 repertoire	 that	 is	 difficult	 to	 predict,	monitor	 and	 control.	 For	
example,	polymorphic	HLA	genotypes	also	limit	the	potential	for	the	use	of	‘off	the	shelf’	T	cell	or	
chimeric	Ag	receptor	(CAR)	T	cell	therapy	because	of	the	danger	of	graft-versus-host	disease.	Here,	
we	 will	 review	 the	 field	 of	 tumor	 immunity	 with	 a	 focus	 on	 the	 role,	 and	 under-explored	
therapeutic	 potential,	 of	 unconventional	 T	 cells	 that	 can	 target	 monomorphic	 Ag-presenting	
molecules	 and	 other	 ligands.	 This	 includes	 the	 MHC	 class	 Ib-restricted	 T	 cells,	 CD1	 and	 MR1	
restricted	 T	 cells,	 and	 γδ	 T	 cells	 (Figure	 1).	 Such	 unconventional	 T	 cells,	 which	 are	 often	





are	 essentially	monomorphic.	 Further,	 unlike	MHC	 class	 Ia,	MHC	 class	 Ib	molecules	 show	 tissue-
restricted	 expression,	 the	 capacity	 to	 assemble	 in	 the	 absence	 of	 peptide,	 or	 a	 propensity	 to	
present	“non-standard”	peptides	(Rodgers	and	Cook,	2005).	Collectively,	these	features	imbue	MHC	





years	 ago	 (Koller	 et	 al.,	 1988;	 Stanton	 et	 al.,	 1978),	 both	 of	 these	molecules	were	 subsequently	
shown	to	acts	as	 ligands	for	members	of	the	NKG2-CD94	NK	receptor	family	(Braud	et	al.,	1998a;	
Vance	et	al.,	1998).	We	now	understand	that	the	function	of	HLA-E	and	Qa-1b	is	the	presentation	of	





inhibitory	 signal	 via	 immunoreceptor	 tyrosine-based	 inhibitory	motifs	 (ITIM),	 preventing	 immune	
activation.	In	this	setting,	it	is	easy	to	envision	that,	by	promoting	the	expression	of	HLA-E,	tumors	
would	 be	 able	 to	 escape	 immune	 detection.	 However,	 HLA-E	 and	 Qa-1b	 are	 also	 ligands	 for	
activating	 NKG2C-CD94	 complexes,	 an	 interaction	 that	 leads	 to	 immune	 activation	 and	 target	
elimination.	 Thus,	 HLA-E	 and	 Qa-1b	 provide	 inhibitory	 and	 activating	 signals	 depending	 on	 the	
context	of	the	receptor	that	is	engaged.	This	understanding	provides	a	rationale	for	the	contrasting	
observations	that	HLA-E	expression	is	associated	with	poor	outcome	in	breast	and	cervical	cancer	
(de	 Kruijf	 et	 al.,	 2010;	 Gooden	 et	 al.,	 2011)	 yet	 can	 be	 used	 as	 a	 good	 prognostic	 indicator	 in	
glioblastoma	(Kren	et	al.,	2011),	colorectal	and	renal	cell	carcinoma	(Benevolo	et	al.,	2011;	Kren	et	
al.,	2012).	These	data	suggest	that,	by	itself,	HLA-E	may	not	be	a	useful	parameter	for	prognosis	but	




Another	 human	 MHC	 class	 Ib	 molecule,	 HLA-G,	 is	 normally	 restricted	 in	 its	 expression	 to	




are	 able	 to	 bind	 inhibitory	 receptors:	 Ig-like	 transcript-2	 (ILT2)	 and	 ILT4,	 which	 in	 turn	 transmit	
inhibitory	 signals	 via	 ITIMs	 (Shiroishi	 et	 al.,	 2003).	 In	 contrast	 to	 HLA-E,	 there	 is	 no	 opposing	
receptor	 that	 transmits	 an	 activating	 signal,	which	 could	make	 increased	HLA-G	an	opportunistic	
mechanism	 for	 tumor	 immune	 evasion.	 Indeed,	 the	 potential	 for	 HLA-G	 to	 regulate	 tumour	
immunity	is	highlighted	by	the	observation	that,	during	neoplastic	transformation	and	growth,	HLA-
G	becomes	prominent	in	hepatocellular	carcinoma	(Catamo	et	al.,	2014;	Lin	et	al.,	2010;	Park	et	al.,	
2012;	 Teixeira	 et	 al.,	 2013),	 colorectal	 and	 renal	 cancers	 (Rouas-Freiss	 et	 al.,	 2017;	 Swets	 et	 al.,	
2016),	 chronic	 myeloid	 leukaemia	 (CML)	 (Caocci	 et	 al.,	 2017)	 and	 glioma	 (Wang	 et	 al.,	 2015).	
However,	 the	 current	 data	 implicating	 HLA-G	 in	 tumour	 evasion	 is	 unclear.	 Meta-analysis	 of	 a	
mutation	 that	 increases	 HLA-G	mRNA	 stability,	 the	 14bp	 ins/del	 (Rousseau	 et	 al.,	 2003),	 has	 no	
prognostic	 value	 for	hepatocellular	 carcinoma(Coelho	et	 al.,	 2016).	 Furthermore,	while	 increased	
levels	of	 soluble	HLA-G	have	been	 identified	as	a	potential	prognostic	 indicator	during	 colorectal	
cancer	progression	(Kirana	et	al.,	2017;	Li	et	al.,	2017),	it	is	unclear	whether	increased	soluble	HLA-
G	 in	 this	 setting	 plays	 a	 role	 in	 suppressing	 the	 immune	 response.	 Modelling	 the	
immunosuppressive	effects	of	HLA-G	in	mouse	models	is	hampered	by	the	fact	that	no	homologue	
exists,	 hence,	 more	 sophisticated	 methods,	 including	 humanised	 mice	 (Nguyen-Lefebvre	 et	 al.,	
2016),	are	required.	
	
Animal	models	of	 cancer	and	MHC	class	 Ib	are	confounded	by	 the	 fact	 that	mice	have	 ten	 times	
more	MHC	 class	 Ib	 genes	 than	 humans.	 Furthermore,	 only	 HLA-E/Qa-1b	 demonstrate	 sufficient	
convergent	 evolution	 that	 their	 functionality	 is	 largely	 unchanged,	 yet	 this	 is	 complicated	by	 the	
observation	that	a	duplicate	of	Qa-1b	exists,	H2-T11,	which	has	almost	identical	functionality	(Chen	
et	al.,	2014).	Despite	 this,	 studies	have	 shown	 that	Qa-1b	plays	a	 critical	 role	 in	 the	detection	of	







evidence	 to	 suggest	 increased	 cancer	 burden	 in	 these	 individuals	 (Zimmer	 et	 al.,	 2005).	
Interestingly,	 TAP-deficient	 patients	 demonstrate	 an	 increase	 in	 NKG2C+	 NK	 cells	 (Béziat	 et	 al.,	











Stroynowski,	 2004),	while	 also	 acting	 to	 prevent	NK	 cell	 control	 of	 tumors	 (Chiang	 et	 al.,	 2002).	
These	 two	 opposing	 effects	 provide	 a	 conundrum	 for	 immune	 editing	 of	 tumors	 whereby	
elimination	 of	 Qa-2	 expression	 will	 prevent	 recognition	 by	 CTL	 but	 also	 removes	 a	 potential	
inhibitory	 ligand	 for	 a	 receptor	 found	on	NK	 cells	 and	 activated/memory	CTL	 (Coles	 et	 al.,	 2000;	
Held	et	al.,	1995).	
	
Given	 the	 expression	 of	 human	MHC	 class	 Ib	molecules	 by	 tumors	 and	 their	 capacity	 to	 impair	
immune	 responses	 through	 specialised	 pathways,	 targeting	 these	 molecules	 as	 a	 cancer	
therapeutic	offers	potential.	However,	translating	observations	from	mouse	models	is	 limited	due	
to	species-based	differences	in	expression	and	function	of	these	molecules.	As	more	sophisticated	





The	 CD1	 family	 of	 Ag-presenting	 molecules	 is	 divided	 into	 two	 groups:	 CD1a,	 CD1b,	 CD1c	 Ag-
presenting	molecules,	collectively	known	as	group	1	CD1	molecules,	and	CD1d	(group	2)	(Godfrey	






group	 2	 CD1	 family	 members.	 The	 majority	 of	 studies	 have	 focussed	 on	 Ag	 recognition	 in	






2004).	 NKT	 cells	 can	 be	 divided	 into	 two	 broad	 types	 –	 based	 on	 their	 TCR	 usage	 and	 lipid	 Ag	
specificity.	 Type	 I	 NKT	 cells	 typically	 express	 semi-invariant	 TCRs	 comprised	 of	 TRAV11	 TRAJ18	
paired	with	a	limited	array	of	TCR-β	chains,	highly	enriched	for	TRBV13,	TRBV29	or	TRBV1	in	mice,	
or	 the	orthologous	TRAV10	TRAJ18	paired	with	TRBV25	 in	humans.	These	 type	 I	NKT	cells	are	all	
strongly	 reactive	 to	 the	glycosphingolipid	Ag	α-galactosylceramide	 (α-GalCer).	Conversely,	 type	 II	
NKT	cells	represent	a	broad	collection	of	T	cells,	excluding	α-GalCer-reactive	cells	with	the	invariant	







studies	 have	 demonstrated	 the	 potential	 for	 type	 I	 NKT	 cells	 to	 inhibit	 tumor	 growth	 in	 mice	
(recently	 reviewed	 in	 (McEwen-Smith	 et	 al.,	 2015;	 Nair	 and	 Dhodapkar,	 2017)).	 Indeed,	 the	 α-




stimulating	 type	 I	NKT	cells	 (Figure	2)	 (Kawano	et	al.,	 1997).	When	presented	by	CD1d,	α-GalCer	




Nicol	 et	 al.,	 2000;	 Smyth	 et	 al.,	 2002)	 although	 this	 is	 not	 the	 only	 means	 by	 which	 NKT	 cells	
mediate	anti-tumor	activity	(Hayakawa	et	al.,	2001;	Metelitsa,	2011;	Smyth	et	al.,	2002).	Activated	
NKT	cells	in	turn	activate	many	other	cells	of	the	immune	system,	and	in	particular,	dendritic	cells	
(DC)	 where	 a	multifactorial	 cross	 talk	 involving	 CD40L-CD40,	 IFNγ	 and	 IL-12	 production	 leads	 to	
increased	expression	of	CD80,	CD86,	CD70	and	IL-12	production	by	the	DC.	This	translates	to	more	
potent	 activation	 of	 conventional	 CD4	 and	 CD8	 T	 cells	 (Fujii	 et	 al.,	 2003;	 Hermans	 et	 al.,	 2003;	
Shimizu	et	al.,	2007;	Silk	et	al.,	2004;	Taraban	et	al.,	2008).	Type	I	NKT	cells	may	also	promote	an	
altered	 DC	 chemokine	 profile	 with	 CCL17	 and	 CCL22	 production	 driving	 the	 recruitment	 of	
functionally	distinct	CCR4+	CD8	T	cells	(Semmling	et	al.,	2010).	In	addition,	other	bystander	cells	are	
activated	 in	this	environment	that	contribute	to	tumor	rejection,	 including	NK	cells	 (Hayakawa	et	
al.,	 2001;	 Smyth	 et	 al.,	 2002),	 and	 γδ	 T	 cells	 (Paget	 et	 al.,	 2012),	 leading	 to	 enhanced	 effector	
function	at	many	levels.	Consequently,	targeting	type	I	NKT	cells	appears	to	engage	several	arms	of	
the	 immune	 system	 at	 once,	 reducing	 the	 potential	 for	 tumor	 escape	 from	 a	 more	 focussed	
immune	response.	Type	I	NKT	cells	can	also	target	tumor-associated	macrophages	(TAMs)	(Song	et	
al.,	 2009),	 myeloid-derived	 suppressor	 cells	 (MDSC)	 (De	 Santo	 et	 al.,	 2008),	 IL-10-secreting	




in	 vitro	 and	 transferring	 these	 cells	 injected	 back	 into	mice,	 which	 promotes	more	 potent	 anti-
tumor	 immunity	 by	 conventional	 CD8	 T	 cells	 compared	 to	 injecting	 this	 Ag	 as	 a	 free	 molecule	
(Shimizu	et	al.,	2007).	Tumors	can	also	be	directly	targeted	in	vivo	using	fusion	proteins	combining	
α-GalCer-CD1d	 to	 scFv	 fragments	 from	 tumor-specific	 antibodies	 (Stirnemann	 et	 al.,	 2008),	
focussing	 the	NKT	cell	 response	 to	 the	 tumor	 site,	 leading	 to	 strong	 inhibition	of	pre-established	
tumors	 compared	 to	 injection	 of	α-GalCer	 alone	 (Stirnemann	 et	 al.,	 2008).	 Another	 approach	 to	
combine	the	adjuvant	activity	of	α-GalCer	to	adaptive	CD8	T	cell	immunity	is	to	directly	conjugate	
α-GalCer	to	tumor	peptide	Ag,	focussing	both	NKT	cells	and	Ag-specific	CD8	T	cells	on	the	same	Ag-
presenting	cells,	 again	 leading	 to	enhanced	CD8	T	 cell-mediated	 tumor	 rejection	compared	 to	α-






et	 al.,	 2005;	 Smyth	 et	 al.,	 2000;	 Swann	 et	 al.,	 2009);	 TRAMP-induced	 carcinoma	 (Bellone	 et	 al.,	
2010);	 transferred	 GM-CSF-secreting	 melanoma	 (Gillessen	 et	 al.,	 2003)	 and	 transferred	 B	
lymphoma	(Renukaradhya	et	al.,	2008).	These	findings	suggest	a	natural	protective	role	for	type	I	
NKT	 cells	 against	 a	 range	 of	 cancer	 types	 in	 mice.	 However,	 some	 caveats	 have	 subsequently	
emerged	 with	 the	 use	 of	 CD1d	 and	 Jα18-deficient	 mice:	 one	 study	 did	 not	 detect	 differential	
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susceptibility	 to	 carcinogen-induced	 sarcoma	 development	 in	 these	 mice	 (Kammertoens	 et	 al.,	
2011),	which	 they	suggested	may	be	due	 to	either	environment	or	genetic	drift	between	strains;	
CD1d-deficient	mice	unexpectedly	harbour	increased	numbers	of	MAIT	cells	compared	to	wildtype	













predictors	 of	 CLL	 progression	 that,	 if	 combined	 with	 current	 prognostic	 factors	 such	 as	 CD38	
expression	 by	 CLL	 cells,	 may	 improve	 prognostic	 accuracy	 in	 this	 type	 of	 cancer.	 Conversely,	 a	






is	 produced	 by	 natural	 gut	 flora	 such	 as	 Bacteroides	 fragilis	 (Wieland	 Brown	 et	 al.,	 2013),	 and	
similar	molecules	such	as	α-psychosine	(Kain	et	al.,	2014)	and	α-Glucosylceramide	(Brennan	et	al.,	
2014)	are	produced	in	multiple	mammalian	tissues	and	can	also	be	detected	in	cow’s	milk	(Brennan	
et	al.,	2017).	Thus,	 it	 is	now	apparent	 that	α-linked	 type	 I	NKT	cell	 ligands	are	present	 in	normal	
healthy	 individuals.	 Furthermore,	 several	 studies	 have	 shown	 that	 tumor	 cells	modulate	 lipid	 Ag	
production	resulting	in	overrepresentation	of	some	lipids	that	may	be	antigenic	for	NKT	cells	when	
presented	in	the	context	of	CD1d,	such	as	isoglobotrihexosylceramide	(iGb3)	(Dias	et	al.,	2009),	the	
gangliosides	GD3	 and	GM3	 (Park	 et	 al.,	 2008;	Wu	et	 al.,	 2003),	 and	α-fucosylceramides	 that	 are	





of	 type	 I	 NKT	 cells	 were	 focussed	 on	 their	 ability	 to	 inhibit	 autoimmune	 diseases	 such	 as	
autoimmune	 (type	 1)	 diabetes	 and	 experimental	 autoimmune	 encephalomyelitis	 (EAE),	 and	 to	
prevent	graft	versus	host	disease	 (Godfrey	and	Kronenberg,	2004).	Accordingly,	 in	 two	studies	of	
haematological	malignancies	in	mice,	type	I	NKT	cells	appeared	to	inhibit	tumor	rejection	(Bjordahl	
et	 al.,	 2012;	 Renukaradhya	 et	 al.,	 2006).	 The	 paradoxical	 ability	 of	 type	 I	 NKT	 cells	 to	 either	
promote,	 or	 suppress,	 cell-mediated	 immunity	 may	 be	 partly	 associated	 with	 diverse	 cytokine	
production	 by	 functionally	 distinct	 subsets	 of	 these	 cells	 in	 response	 to	α-GalCer.	 These	 include	
















deep	within	 the	 hydrophobic	 Aʹ-	 and	 Fʹ-pockets	 of	 CD1d,	 respectively,	while	 the	 polar	 galactose	
moiety	protrudes	out	of	 the	CD1d	binding	 cleft	 for	 recognition	by	 the	 type	 I	NKT	TCR	 (Figure	2),	
which	adopted	a	highly	 conserved	parallel	docking	mode	over	 the	Fʹ-pocket	of	 the	CD1d	binding	
groove	whereby	the	invariant	TCR	α-chain	made	key	interactions	with	the	2ʹ-,	3ʹ-	and	4ʹ-hydroxyls	
of	α-GalCer	and	CD1d,	while	the	NKT	TCR	β-chain	mediated	 interactions	exclusively	with	CD1d.	A	
number	 of	 CD1d	 residues	 also	 interacted	 closely	 with	 the	 O-glycosidic	 oxygen,	 the	 2ʹ-	 and	 3ʹ-
hydroxyls	of	α-GalCer,	and	 thus	 stabilizing	 the	Ag	within	 the	CD1d	cleft.	These	structural	 insights	
into	 the	CD1d-α-GalCer-type	 I	NKT	TCR	molecular	 interactions	provided	a	highly	valuable	rational	
basis	 to	 design	 novel	 classes	 of	 α-GalCer	 analogues	 (Figure	 2)	 that	 impact	 the	 type	 I	 NKT	 TCR	
recognition	and	direct	a	more	favourable	Th1	skewed	immune	response	for	cancer	therapy.	Indeed,	
presently	 the	molecular	 presentation	 and/or	 recognition	 of	 total	 of	 over	 20	 α-GalCer	 analogues	
have	been	investigated	structurally	although	fine	specificity	differences	between	mouse	and	human	
type	 I	 NKT	 cells	 may	 complicate	 translation	 of	 findings	 from	 mouse	 to	 human-based	 studies	
(Birkholz	 et	 al.,	 2015;	 Li	 et	 al.,	 2009;	 Wun	 et	 al.,	 2012).	 In	 brief,	 the	 introduced	 chemical	
modifications	 have	 been	 mainly	 targeting	 three	 distinct	 parts	 of	 the	 α-GalCer	 molecule	 that	
included	 the	 O-glycosidic	 bond,	 the	 glycolipid	 hydrophobic	 tails,	 and	 the	 galactose	 C6ʹ	 hydroxyl	
(Figure	2).	 Collectively,	 these	 approaches	have	 resulted	 in	new	glycolipid	 analogues	 such	as	α-C-
GalCer	(Patel	et	al.,	2011;	Schmieg	et	al.,	2003), aminocyclitolic	ceramide	(Kerzerho	et	al.,	2012),	β-
mannosylceramide	 (O'Konek	 et	 al.,	 2011),	 Nu-α-GalCer	 (Aspeslagh	 et	 al.,	 2011),	 PyrC-α-GalCer	
(Aspeslagh	et	al.,	2013),	α-GalCer	analogues	with	aromatic	 rings	 in	 their	acyl	or	 sphingosine	 tails	
(Chang	et	al.,	2007),	and	ABX196,	an	α-GalCer	analogue	with	an	acetamide	group	appended	to	the	





(Chang	 et	 al.,	 2005;	 Ishikawa	 et	 al.,	 2005;	 Nieda	 et	 al.,	 2004),	 demonstrated	 that	 these	 agents,	
which	were	 generally	well-tolerated	with	 no	 serious	 complications,	 could	 induce	 type	 I	 NKT	 cell	
expansion,	 cytokine	 production	 and	 activation	 of	 bystander	 cells.	 One	 of	 these	 studies	 also	




al.,	 2011a;	Richter	 et	 al.,	 2012;	Uchida	et	 al.,	 2008)	have	 further	demonstrated	 that	 this	 form	of	
	 8	
therapy	 has	 the	 potential	 to	 cause	 tumor	 regression	 or	 stabilise	 cancer	 growth	 in	 a	 subset	 of	
patients.	In	one	study,	α-GalCer	was	pulsed	onto	autologous	IL-2	and	GMCSF-cultured	PBMC,	which	
were	 then	 injected	 back	 into	 patients	 with	 advanced	 non-small	 cell	 lung	 cancer	 (NSCLC).	 In	 the	
majority	 (10	 out	 of	 17)	 of	 patients	 where	 a	 strong	 IFNγ	 response	 was	 observed,	 their	 median	
survival	time	was	31.9	months,	compared	to	~10	months	for	the	poor	responders,	which	is	closer	to	
expected	 for	 standard	 care	 for	 patients	 with	 advanced	 NSCLC	 (Motohashi	 et	 al.,	 2009).	 An	
additional	 approach	 has	 been	 to	 inject	 in	 vitro	 expanded	 and	 activated	 autologous	 NKT	 cells	
(Motohashi	et	al.,	2006)	 sometimes	 in	combination	with	α-GalCer	 loaded	dendritic	 cells	 (Kunii	et	
al.,	 2009;	 Yamasaki	 et	 al.,	 2011).	 A	 recent	 clinical	 trial	 has	 been	 reported	 where	α-GalCer	 was	
combined	 with	 a	 defined	 tumor	 protein	 Ag,	 NY-ESO-1,	 both	 loaded	 onto	 DC	 and	 injected	 into	
melanoma	patients	(Gasser	et	al.,	2017).	This	induced	a	sustained	increase	in	NY-ESO-1	responsive	
CD4	and	CD8	T	cells	 in	7	of	8	subjects,	highlighting	 the	potential	benefits	of	 targeting	 type	 I	NKT	
cells	in	association	with	tumor	Ag	vaccines.	While	these	reports	are	typically	from	small-scale	pilot	
studies	 or	 phase	 I	 or	 II	 trials,	 they	 are	 nonetheless	 providing	 encouraging	 results	 with	 tumor	
stabilisation	and	in	some	cases,	tumor	regression	(Table	1).	The	first	clinical	trial	with	an	enhanced	
potency	α-GalCer	analogue	(ABX196)	as	an	adjuvant	for	a	prophylactic	HepB	vaccine	was	recently	
reported	 (Tefit	 et	 al.,	 2014).	 This	work	 showed	 that	 type	 I	 NKT	 cell	 targeting	with	 this	 analogue	
could	 induce	 a	 potent	 anti-HepB	 antibody	 response	 from	 a	 single	 injection,	 comparable	 to	 the	
prime	 and	 boost	 response	 with	 the	 existing	 HepB	 vaccine	 with	 conventional	 Alum	 adjuvant.	 As	
HepB	 infection	 is	 associated	 with	 an	 increased	 risk	 of	 hepatocellular	 carcinoma,	 this	 highlights	
another	 potential	 means	 by	 which	 NKT	 cell	 targeting	 can	 be	 employed	 as	 a	 cancer	
immunotherapeutic.	Moreover,	the	successful	use	of	the	ABX196	analogue	in	this	setting	flags	the	
importance	 of	 testing	 this	 and	 other	α-GalCer	 analogues	 in	 direct	 anti-tumor	 clinical	 trials.	 The	






expressed	 in	neuroblastoma	 (NB)	were	 cytotoxic	 against	human	NB	cells	 in	 vitro	 and	 in	 vivo	 in	 a	
humanised	NOD-SCID-IL2Rγnull	(NSG)	mouse	tumor	model.	Moreover,	while	both	GD2-specific	CAR-
T	 cells	 and	 CAR-NKT	 cells	were	 capable	 of	 infiltrating	 the	NB	 tumors,	 the	 CAR-NKT	 cells	 did	 this	
more	 effectively.	 Furthermore,	 CAR-T	 cells	 generated	 from	 an	 allogeneic	 donor	 caused	 severe	
GVHD	in	the	NSG	mice,	whereas	this	did	not	happen	with	GD2-specific	CAR-NKT	cells	(Heczey	et	al.,	
2014).	This	highlights	the	advantage	of	using	NKT	cells,	and	potentially	other	unconventional	T	cells,	




very	 diverse,	 and	 there	 is	 no	 universal	 type	 II	 NKT	 cell	 antigen	 that	 can	 be	 used	 to	 study	 this	
population	 of	 T	 cells.	 Consequently,	 the	 functional	 role	 of	 these	 type	 II	 NKT	 cells	 is	 less	 clear	
(recently	reviewed	in	(Dhodapkar	and	Kumar,	2017)),	although	important	to	establish	as	they	may	
be	 more	 prevalent	 in	 humans	 than	 type	 I	 NKT	 cells(Exley	 et	 al.,	 2001).	 While	 only	 a	 few	
investigations	into	the	role	of	type	II	NKT	cells	in	cancer	have	been	published,	most	studies	suggest	




data	 suggested	 that	 type	 II	 NKT	 cells	 suppress	 tumor	 rejection	 through	 the	 production	 of	 IL-13	
(Terabe	et	al.,	2005).	 In	 further	 support	 for	an	 immunosuppressive	 function	 for	 type	 II	NKT	cells,	
when	tumor	bearing	mice	are	treated	with	the	glycolipid	Ag	sulfatide,	which	is	presented	by	CD1d	
to	 a	 subset	 of	 type	 II	 NKT	 cells,	 tumor	 growth	 was	 exacerbated	 through	 production	 of	 IL-13	
(Ambrosino	 et	 al.,	 2007).	 Moreover,	 type	 II	 NKT	 cell-mediated	 suppression	 can	 antagonise	 the	
protective	 effects	 induced	 by	 α-GalCer-mediated	 type	 I	 NKT	 cell	 stimulation	 (Ambrosino	 et	 al.,	
2007;	Halder	et	al.,	2007).	A	more	recent	study	suggested	that	type	II	NKT	cells	and	Treg	cells	both	
play	 an	 immunosuppressive	 role	 and	 that	 blockade	 of	 both	 cell	 types	was	 necessary	 to	 prevent	
tumor	 immunosuppression	 when	 type	 I	 NKT	 cells	 are	 absent	 (Izhak	 et	 al.,	 2013).	 Another	












It	 is	 well	 known	 that	 CD1a,	 CD1b	 and	 CD1c	 restricted	 T	 cells	 are	 capable	 of	 presenting	
mycobacterial	lipid	Ags	to	human	T	cells	(Van	Rhijn	et	al.,	2015).	Furthermore,	recent	studies	have	
demonstrated	 that	 some	 T	 cells	 are	 capable	 of	 interacting	 with	 self-lipid	 Ags	 (Birkinshaw	 et	 al.,	
2015;	de	Jong	et	al.,	2010;	de	Lalla	et	al.,	2011;	Shahine	et	al.,	2017;	Van	Rhijn	et	al.,	2016;	Wun	et	
al.,	2018),	including	skin-derived	lipids	(de	Jong	et	al.,	2014)	presented	by	group	1	CD1	molecules.	
Moreover,	 some	 appear	 to	 interact	 solely	 with	 CD1a	 and	 CD1c	 in	 a	 response	 that	 is	 indirectly	
modulated	by	the	bound	lipid	Ag	(Birkinshaw	et	al.,	2015;	Wun	et	al.,	2018).	Furthermore,	CD1a,	b	
and	 c	 are	 expressed	 by	 human	 DC,	 so	 these	molecules	 are	 present	 in	 the	 tumor	 and/or	 tumor	




leukemia	 cells.	 These	 T	 cells	 were	 capable	 of	 killing	 human	 leukemia	 cells	 in	 vitro,	 and	 in	 a	
xenogeneic	mouse	 tumor	 transplantation	model.	 In	another	 study,	using	mice	 that	 transgenically	
expressed	 group	 1	 CD1	 molecules,	 CD1b-self-phospholipid-reactive	 T	 cells	 were	 capable	 of	
responding	to	tumor-derived	phospholipids	and	conferred	protection	against	a	CD1b-transfected	T	
cell	 lymphoma	 (Bagchi	 et	 al.,	 2016).	 Even	 if	 specific	 tumor	 lipid	Ags	 do	not	 exist	 for	 each	of	 the	
group	1	CD1	molecules,	 the	existence	of	known	 foreign	agonist	 ligands	 raises	 the	possibility	 that	
group	1	CD1-restricted	T	cells	 could	be	 targeted	 for	cancer	 immunotherapy,	much	 the	same	way	
that	 type	 I	 NKT	 cells	 can	 be	 targeted	 with	 the	α-GalCer.	 For	 example,	 most	 humans	 harbour	 a	
population	of	CD1b-restricted	T	cells	known	as	 ‘germline	encoded	mycolyl-reactive’	 (GEM)	T	cells	
that	 express	 an	 invariant	 TRAV1-2-TRAJ9	 TCR-α	 chain	 (Van	 Rhijn	 et	 al.,	 2013).	 This	 TCR	 imbues	
these	 cells	with	 specificity	 for	 the	mycobacterial	 lipid	Ag	 glucose	monomycolate,	 and	 these	 cells	
rapidly	produce	IFNγ	upon	Ag	encounter.	It	is	noteworthy	that	glucose	monomycolate	is	present	in	
the	mycobacterial	bacillus	Calmette	Guerin	 (BCG)	vaccine	 strain,	 and	 that	BCG-based	 therapy	 for	
non-muscular	bladder	cancer	has	been	successfully	for	many	years(Morales	et	al.,	1976).	Given	that	
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the	mechanism	 of	 action	 for	 BCG-based	 immunotherapy	 is	 unclear,	 but	 involves	 both	 CD4+	 and	
CD8+	T	cells	 (Redelman-Sidi	et	al.,	2014)	and	 that	 the	majority	of	BCG-responsive	CD8	T	cells	are	
CD1a,	 b	 or	 c	 restricted	 (Kawashima	 et	 al.,	 2003),	 the	 potential	 for	 mycobacterial	 lipid-based	
immunotherapy	to	target	group	1	restricted	T	cells	like	GEM	T	cells	is	worthy	of	further	exploration.	
	









MAIT	 cells	 are	 innate-like	 T	 cells	 found	 in	 mammals,	 whose	 frequency	 varies	 between	 species	
(Godfrey	 et	 al.,	 2015).	 	 For	 example,	whilst	 abundant	 in	 humans	 they	 are	much	 less	 frequent	 in	
laboratory	 strains	 of	mice	 (Rahimpour	 et	 al.,	 2015;	 Reantragoon	et	 al.,	 2013;	 Tilloy	 et	 al.,	 1999).	
MAIT	cells	reside,	as	their	name	implies,	in	the	mucosa,	and	are	also	found	in	the	peripheral	blood,	
and	organs	such	as	the	liver.	Although	the	physiological	and	pathophysiological	roles	for	MAIT	cells	
are	unclear,	 it	 is	 known	 that	many	bacteria	and	yeast	activate	MAIT	 cells	 via	 the	MAIT	TCR-MR1	
axis(Gold	et	al.,	2010;	Le	Bourhis	et	al.,	2010).	Moreover,	MAIT	cells	can	be	activated	by	viruses	in	a	
MAIT	 TCR-independent	 manner	 (Loh	 et	 al.,	 2016;	 van	Wilgenburg	 et	 al.,	 2016).	 	 MAIT	 cells	 are	
thought	to	play	a	role	 in	protective	 immunity	to	bacteria	(Chen	et	al.,	2016;	Howson	et	al.,	2018;	
Meierovics	et	al.,	2013),	and	are	reported	to	be	depleted	during	infection	by	viruses(Ussher	et	al.,	
2018),	which	 is	 considered	 to	 increase	host	 susceptibility	 to	opportunistic	 infections.	 In	 addition,	




IFN-γ,	TNF	and,	 in	some	situations	 IL-17,	 following	TCR-mediated	activation	 (Salio	et	al.,	2014).	 In	
line	with	 their	 innate-like	phenotype,	 the	majority	of	MAIT	 cells	 typically	possess	a	highly	biased	
TCR	 repertoire,	 characterised	 by	 a	 near-invariant	 TCR	 α-chain	 (TRAV1-2-TRAJ33	 or	 TRAJ12	 or	
TRAJ20)	 and	 a	 biased	 usage	 of	 TCR	 β	 chains	 (TRBV6	 or	 TRBV20),	 although	 the	 CDR3β loop	 is	
hypervariable(Eckle	et	al.,	2014;	Porcelli	et	al.,	1993;	Reantragoon	et	al.,	2013;	Tilloy	et	al.,	1999).	In	
contrast	to	type	I	NKT	TCR,	the	MAIT	TCR	recognises	the	MHC-I	related	molecule,	MR1(Treiner	et	
al.,	 2003).	 However,	 while	 MR1	 is	 expressed	 in	 all	 cell	 types,	 endogenous	 MR1	 cell	 surface	
expression	 is	 low,	and	 it	 is	 known	 that	 the	presence	of	MR1	 ligands	are	 required	 to	enable	MR1	
egress	to	the	cell	surface(McWilliam	et	al.,	2016).	These	MR1	ligands	were	identified	as	vitamin	B-
related	 ligands	 that	 bound	 MR1	 and	 activated	 MAIT	 cells	 with	 varying	 potencies	 (Figure	 3).	
Specifically,	while	MR1	bound	to	pterins	(metabolites	of	folic	acid	(vitamin	B9))	such	as	6-FP	and	the	
synthetic	 analogue	 acetyl-6-FP	 (Ac-6-FP),	 they	 typically	 do	 not	 activate	MAIT	 cells	 (Awad	 et	 al.,	
2018).	 In	 contrast,	 ribityllumazines	 (precursors	 to	 riboflavin	 (vitamin	 B2))	 bind	 MR1	 and	 also	
activate	MAIT	cells	weakly,	while	the	most	potent	agonists	were	derived	through	condensation	of	
an	 intermediate	 (5-amino-6-D-ribitylaminouracil,	 5-A-RU)	 in	 riboflavin	 biosynthesis	with	 glycolysis	
metabolites	 produced	 by	 bacteria	 and	 humans	 to	 form	 ribityluracils	 (e.g.	 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil,	 5-OP-RU)	 (Corbett	 et	 al.,	 2014;	 Kjer-Nielsen	 et	 al.,	
2012;	 Patel	 et	 al.,	 2013).	 Further,	 it	 has	 recently	 been	 demonstrated	 that	 MR1	 can	 present	 a	
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broader	 range	 of	 chemical	 scaffolds,	 including	 drugs	 and	 drug-like	molecules(Keller	 et	 al.,	 2017),	
which	 suggest	 that	 other	 endogenous	 ligands,	 can	 modulate	 MAIT	 cell	 function	 in	 an	 MR1-
dependent	manner.	Using	these	5-OP-RU	and	6-FP/Ac-6-FP	 ligands,	MR1-Ag	tetramers	have	been	
generated	that	permit	MAIT	cell	phenotyping	ex	vivo	in	an	Ag-specific	manner	(Corbett	et	al.,	2014;	
Rahimpour	et	al.,	 2015;	Reantragoon	et	al.,	 2013).	Using	 these	 tetramers	 (which	are	now	readily	
available	 from	 the	 NIH	 tetramer	 facility,	 http://tetramer.yerkes.emory.edu/),	 previously	
unrecognised	 subsets	 of	 MAIT	 cells	 are	 being	 identified,	 including	 immature	 precursors	 (Ben	
Youssef	et	al.,	2018;	Koay	et	al.,	2016)	and	MR1-restricted	TRAV1-2-	T	cells	 that	bind	 to	5-OP-RU	
and/or	 folate-derived	 ligands	6-FP	 and	Ac-6-FP	 (Gherardin	 et	 al.,	 2016).	 Further,	 the	use	of	MR1	






While	 there	are	no	known	MR1-binding	tumor	Ags	 that	activate	MAIT	cells,	 it	 is	conceivable	 that	
MAIT	cells	may	encounter	microbial	Ags	in	tumor	types,	such	as	mucosal	cancers,	where	bacterial	
infiltrates	are	likely	to	be	present.	Furthermore,	as	observed	in	viral	infections	(Ussher	et	al.,	2018),	
MAIT	 cells	 can	 be	 activated	 in	 the	 presence	 of	 inflammatory	 cytokines,	 such	 as	 IL-12	 and	 IL-18,	
without	specific	Ag	stimulation.	TRAV1-2The	first	report	to	document	the	presence	of	MAIT	cells	in	
human	 cancers	 showed	 the	 presence	 of	 TRAV1-2-TRAJ33	 transcripts	 that	were	 enriched	 in	 brain	
and	 kidney	 tumors	 (Peterfalvi	 et	 al.,	 2008).	More	 recently,	 in	 a	 study	 of	 cancer	 patients	 with	 a	
variety	 of	 cancer	 types,	MAIT	 cells	 (defined	 by	 co-expression	 of	 surrogate	markers	 TRAV1-2	 and	
CD161	 or	 CD218)	 were	 found	 to	 be	 diminished	 in	 the	 circulation	 of	mucosal-associated	 cancers	
(gastric,	colon	and	lung),	but	not	in	association	with	non-mucosal	cancers	(breast,	liver	and	thyroid)	
(Won	et	al.,	2016).	Furthermore,	in	a	group	of	colon	cancer	patients,	where	circulating	MAIT	cells	







Because	MAIT	cells	are	highly	abundant	 in	human	 liver	 (Dusseaux	et	al.,	2011;	Tang	et	al.,	2013),	
the	role	that	these	might	play	in	liver-localised	cancers	is	of	particular	interest.	One	study	reported	
that	MAIT	 cells	 are	 present	 in	 both	 the	 healthy	 parts	 of	 liver	 as	 well	 as	 the	 tumor	 infiltrate	 in	
colorectal	 liver	metastasis	patients,	but	those	isolated	from	the	tumor	margin,	or	from	within	the	
tumor,	 were	 functionally	 impaired	 in	 their	 ability	 to	 produce	 IFN-γ	 (Shaler	 et	 al.,	 2017).	 Along	
similar	lines,	a	single	cell	sequencing	study	of	hepatocellular	carcinoma	patient	liver	samples,	MAIT	
cells	were	found	to	be	abundant	in	healthy	liver	tissue,	but	diminished	in	number	in	the	tumour	site	
(Zheng	 et	 al.,	 2017).	Moreover,	 reduced	MAIT	 cell	 frequencies	 appeared	 to	 correlate	 with	 poor	
prognosis	 in	these	patients	(Zheng	et	al.,	2017).	These	studies	suggest	that	inhibition	of	MAIT	cell	
infiltration	 and/or	 function	may	 be	 important	 for	 tumor	 survival.	 In	multiple	myeloma	 patients,	
MAIT	cells	are	also	numerically	and	functionally	diminished	in	blood	and	bone	marrow	(tumor	bed),	
although	 in	 part	 this	may	 reflect	 the	 older	 ages	 of	 these	 patients	 (Gherardin	 et	 al.,	 2018a).	 This	
study	also	showed	that	myeloma	cell	lines	expressed	cell	surface	MR1,	which	was	increased	in	the	












role	 in	 the	 response	 to	 cancer;	 and	 (4)	 Do	 MAIT	 cells	 respond	 directly	 to	 tumors	 or	 do	 they	
modulate	the	activity	of	other	immune	cells.	Further	studies	could	compare	tumor	development	in	
MR1-deficient	 mice	 that	 lack	 MAIT	 cells	 to	 wildtype	 MAIT	 cell-sufficient	 mice.	 Mice	 that	 have	
increased	MAIT	 cells	 such	 as	 C57BL/6CAST	 congenic	mice	 (Cui	 et	 al.,	 2015b),	 or	where	MAIT	 cells	
have	been	 expanded	 in	 vivo	 (Chen	 et	 al.,	 2017)	may	provide	 a	 better	 indication	of	 the	 role	 that	
MAIT	cells	play	in	cancer,	whereas	Va19	TCR	transgenic	mice	might	not	be	helpful	for	these	studies	
as	 their	MAIT	 cells	 appear	 to	 be	 developmentally	 and	 functionally	 altered	 compared	 to	 those	 in	
non-transgenic	 mice	 (Koay	 et	 al.,	 2016).	 Complementing	 the	 use	 of	 different	 MAIT-deficient	 or	
sufficient	mouse	strains,	the	use	of	MAIT	cell	agonist	ligands	such	as	5-OP-RU	(Corbett	et	al.,	2014)	
to	 activate	MAIT	 cells	 in	 the	 context	 of	 tumor	 development	 in	 vivo	 is	 also	 a	 logical	 approach	 to	








in	 the	 circulation	and	 react	 to	 small	 phosphorylated	metabolite	Ags,	 known	as	phosphoantigens,	
that	are	typically	derived	from	foreign	pathogens,	but	are	also	produced	by	mammalian	cells	and	
can	 lead	to	 increased	expression	by	 tumor	cells.	The	TRDV2-	cells	often	utilize	TRDV1+	or	TRDV3+	
TCRs	 and	 localize	 to	 peripheral	 sites	 such	 as	 skin	 and	 large	 intestine.	 There	 is	 only	 limited	
knowledge	about	 their	Ag	 reactivity,	 although	some	can	 react	with	MHC-I	 like	molecules	 such	as	
MICA,	CD1	and	EPCR,	or	soluble	Ags	in	the	absence	of	Ag-presentation,	in	sharp	contrast	to	other	
types	of	 T	 cells	 (reviewed	 in	 (Godfrey	et	 al.,	 2015;	Vantourout	and	Hayday,	2013)).	 Interestingly,	
some	TRDV1+	γδ	T	cells	can	respond	to	α-GalCer	presented	by	CD1d	in	humans(Uldrich	et	al.,	2013),	






While	 the	major	 focus	 for	 the	 function	 of	 γδ	 T	 cells	 has	 been	 their	 role	 in	 homeostasis,	 wound	
repair	and	infection	(Nielsen	et	al.,	2017),	there	is	also	great	interest	in	the	role	that	these	cells	play	




is	 possible	 to	 isolate	 them	 in	 relatively	 large	 numbers	 and	 most	 have	 a	 Th1-type	 cytokine	 bias	
(strong	 IFN-γ	 production)	 and	potent	 cytotoxicity	 potential,	 attributes	 that	 are	 closely	 correlated	
with	tumor	destruction.	They	readily	expand	following	TCR	stimulation	in	vitro,	thereby	increasing	
the	 feasibility	of	 their	usage	 in	adoptive	 transfer	models	of	 therapy	and	 furthermore,	many	γδ	T	
cells	have	unique	homing	properties	compared	to	αβ	T	cells,	typically	migrating	to	peripheral	sites,	
such	as	epithelial	tissues	and	solid	tumors.	Finally,	 like	other	unconventional	T	cells,	γδ	T	cells	are	





Evidence	 for	 a	 role	 of	 γδ	 T	 cells	 in	 cancer	 surveillance	 first	 arose	 from	 studies	 using	 γδ	 T	 cell-
deficient	mice.	 These	 studies	 indicated	 a	 significantly	 elevated	 incidence	 of	 tumors	 in	models	 of	
chemically-induced	cutaneous	malignancies	(Gao	et	al.,	2003;	Girardi	et	al.,	2001)	and	spontaneous	
prostate	 adenocarcinoma	 (Liu	 et	 al.,	 2008),	 compared	 to	 control	 wild-type	 mice.	 Experimental	
transfer	 of	 established	 tumor	 cell	 lines	 derived	 from	 melanoma	 (Gao	 et	 al.,	 2003)	 and	 B	 cell	
lymphoma	 (Street	 et	 al.,	 2004)	 also	 confirmed	 a	 beneficial	 role	 of	 γδ	 T	 cells	 (reviewed	 in	 (Silva-
Santos	et	al.,	2015)).	Consistent	with	animal	 studies,	human	γδ	T	 cells	 can	also	elicit	 strong	anti-
tumor	 responses	 in	 vitro.	 Activated	 TRDV2+	 γδ	 T	 cells	 recognize	 and	 kill	 a	 broad	 range	 of	 tumor	
target	 cells	 in	 vitro	 (Bouet-Toussaint	 et	 al.,	 2008;	 Corvaisier	 et	 al.,	 2005;	 Kunzmann	 et	 al.,	 2000;	
Lanca	 et	 al.,	 2010;	 Liu	 et	 al.,	 2005;	 Viey	 et	 al.,	 2005).	 Likewise,	 activated	 TRDV1+	 cells	 can	 also	
recognize	 and	 kill	 diverse	 tumor	 lines	 representing	 many	 cancer	 types	 (Choudhary	 et	 al.,	 1995;	
Cordova	et	al.,	2012;	Correia	et	al.,	2011;	Groh	et	al.,	1999;	Lamb	et	al.,	2001;	Maeurer	et	al.,	1996).		
	
The	 association	 between	 γδ	 T	 cells	 and	 tumor	 progression	 and/or	 patient	 survival	 has	 been	
examined	in	a	range	of	different	human	tumor	settings,	with	contrasting	results.	Bialasiewicz	et	al.	
((Bialasiewicz	et	al.,	1999))	found	that	γδ	T	cells	amongst	tumor-infiltrating	lymphocytes	(TILs)	were	
positively	 associated	 with	 patient	 survival	 in	 choroidal	 melanoma.	 Another	 study	 of	 melanoma	
patients	found	that	TRDV2+	γδ	T	cells	were	positively	associated	with	survival	at	an	early	stage	of	
disease	(Cordova	et	al.,	2012),	and	a	follow	up	study	extended	this	correlation	with	overall	patient	
survival	 (Toia	 et	 al.,	 2016).	 Studies	 of	 patient	 cohorts	 that	 received	 allogeneic	 bone	 marrow	
transplantation	revealed	a	strong	correlation	between	γδ	T	cell	abundance	and	overall	survival	or	
disease-free	 survival	 in	 cohorts	 of	 ALL	 or	 acute	 myeloid	 leukemia	 (AML),	 or	 chronic	 myeloid	
leukemia	 (CML)	 patients	 (Godder	 et	 al.,	 2007;	 Lamb	 et	 al.,	 1996).	 Moreover,	 activated	 donor-
derived	γδ	T	cells,	which	were	predominantly	TRDV1+,	were	cytotoxic	against	recipient	ALL	tumors	
(Lamb	 et	 al.,	 2001)	 in	 vitro,	 suggesting	 a	 potentially	 important	 role	 for	 γδ	 T	 cells	 in	 immune	
surveillance	against	leukemia.	Despite	these	promising	findings,	in	some	settings	γδ	T	cells	do	not	
appear	 to	be	a	useful	prognostic	marker	 (Inman	et	al.,	 2008;	Kuriyama	et	al.,	 2000),	or	are	even	
associated	with	poor	outcome	or	tumor	burden,	indicative	of	a	pro-tumorigenic	role.	For	instance,	
in	 rectal	 cancer	 patients,	 while	 TRDV1+	 γδ	 T	 cells	 amongst	 TILs	 positively	 correlated	with	 tumor	
burden,	TRDV2+	cells	negatively	correlated,	 indicating	a	differential	role	of	these	subsets	(Rong	et	
al.,	 2016).	 Another	 study	 also	 found	 an	 association	 between	 IL17-producing	 γδ	 T	 cells	 and	 poor	
survival	in	gall	bladder	patients	(Patil	et	al.,	2016),	and	in	primary	breast	cancer	patients,	γδ	T	cells	
were	associated	with	more	severe	disease	and	reduced	overall	survival,	indicating	a	pro-tumor	role	
(Ma	 et	 al.,	 2012).	 In	 support	 of	 this	 notion,	 Peng	 et	 al.	 (Peng	 et	 al.,	 2007)	 isolated	 a	 regulatory	
population	of	TRDV1+	γδ	T	cells	from	breast	cancer	TILs	that	specifically	recognized	a	tumor	epitope	
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via	 the	γδTCR,	and	exhibited	 immune-suppressive	 functions	 that	 could	be	 reversed	 in	vitro	using	
TLR8	ligands.		
	
Further	 insight	 into	 the	 pro-	 versus	 anti-	 tumor	 role	 of	 γδ	 T	 cells	 can	 be	 gleaned	 from	 mouse	
studies.	 In	many	 cases,	 the	 protective	mechanisms	 appeared	 to	 involve	 interaction	with	 NK	 cell	
receptors	 such	 as	NKG2D,	which	 can	 recognize	 stress-associated	 receptors	 on	 transformed	 cells,	
along	with	IFNγ	production,	which	promotes	Th1	responses	that	are	generally	favorable	in	an	anti-
cancer	 immunotherapeutic	 setting.	 Another	 population	 of	 clonally	 expanded	 TRDV5+	 γδ	 T	 cells	
isolated	from	a	CMV-infected	patient	was	capable	of	killing	tumor	lines	through	recognition	of	the	
MHC-I	like	molecule	EPCR	(Willcox	et	al.,	2012),	suggesting	that	this	ligand	may	be	involved	in	γδ	T	
cell-mediated	 immunosurveillance,	 although	 further	 investigation	 is	 required.	 Whilst	 in	 some	
studies,	γδ	T	cell-derived	IL-17	exhibited	anti-tumor	effects	(Ma	et	al.,	2011;	Takeuchi	et	al.,	2011),	
it	 has	 also	 been	 associated	 with	 pro-tumor	 responses,	 along	 with	 regulatory	 cell-like	 functions,	
enhanced	angiogenesis,	and	neutrophil	or	MDSC	recruitment	(reviewed	 in	(Fleming	et	al.,	2017)).	








2003;	 Wilhelm	 et	 al.,	 2014)	 (Table	 2).	 These	 trials	 typically	 involved	 either	 in	 vitro	 or	 in	 vivo	
expansion	of	TRDV2+	γδ	T	cells	using	aminobisphosphonates,	such	as	zoledronate,	which	cause	an	
accumulation	 of	 the	 phosphoantigen	 isopentenyl	 pyrophosphate	 (IPP);	 or	 phosphoantigens	
directly.	Whilst	there	were	no	significant	adverse	effects	of	therapy	 in	these	studies,	complete	or	
even	partial	responses	were	relatively	infrequent,	although	of	note,	Wilhelm	et	al.	((Wilhelm	et	al.,	
2014))	 transferred	 HLA-half-matched,	 CD4	 and	 CD8-depleted	 cells	 into	 4	 patients	 with	
haematological	malignancies,	followed	by	in	vivo	γδ	T	cell	activation	using	zoledronate	and	IL-2,	of	





therapeutically	 beneficial	 in	 a	 xenogeneic	 model	 of	 human	 ovarian	 cancer,	 where	 adoptively	
transferred	 activated	 TRDV1	 cells	were	 largely	 protective	 (Deniger	 et	 al.,	 2014a),	 suggesting	 that	
clinical	studies	may	be	warranted.	Clearly	more	research	 is	required	to	understand	the	functional	














Vδ2+	 γδ	 T	 cells	 outnumber	 pMHC-specific	 CD8	 T	 cells	 by	 2-4	 orders	 of	 magnitude	 in	 humans	
(Godfrey	et	al.,	2015).	Furthermore,	the	adjuvant-like	effects	and	strong	cytokine	responses	upon	
activation	of	 some	of	 these	cells,	 such	as	 type	 I	NKT	cells,	engages	multiple	arms	of	 the	 immune	
system	 that	 should	 help	 to	 guard	 against	 the	 formation	 of	 tumor	 escape	 variants.	 The	 Ag-
presenting	 molecules	 for	 unconventional	 T	 cells	 are	 monomorphic	 and	 thus	 Ag-based	 vaccines	
targeting	these	cells	could	be	universally	effective	with	respect	to	human	cancer	patients.	This	also	
means	that	their	TCRs,	which	are	not	directed	toward	polymorphic	MHC	molecules,	will	be	unlikely	
to	mount	 alloreactive	 responses	 and	 cause	GVHD,	making	 these	 cells	more	 amenable	 to	 off	 the	
shelf	cellular	therapy	such	as	CAR-NKT	cell	therapy	(Heczey	et	al.,	2014;	Tian	et	al.,	2016).	Further,	
many	 of	 these	 unconventional	 T	 cells	 express	 TCRs	 with	 repeated	 patterns	 of	 TCR	 usage	 in	
unrelated	 individuals,	 which	 means	 that	 they	 could	 also	 potentially	 represent	 targets	 for	







While	 many	 clinical	 trials	 on	 unconventional	 T	 cells	 have	 focussed	 on	 the	 use	 of	 α-GalCer	 to	
stimulate	 type	 I	 NKT	 cells,	 future	 studies	 exploring	 the	 new	 lipid	 analogues	 (Figure	 2)	 should	
provide	 improved	 clinical	 outcomes.	Moreover,	 while	 targeting	 Ags	 recognised	 by	 group	 1	 CD1-
restricted	 T	 cells	 is	 in	 its	 infancy	 this	 also	warrants	 further	 investigation	 in	 the	 context	 of	 tumor	
immunotherapy.	Clinical	trials	targeting	TRDV1+	γδ	T	cells	may	offer	improved	outcomes	over	those	
targeting	TRDV2+	γδ	T	cells,	because	the	 former	tend	to	 localise	 to	non-lymphoid	tissue	 locations	




like	 5-OP-RU	 that	 can	 target	 these	 cells	 in	 all	 individuals.	 Studies	 using	 MR1	 restricted	 Ags	 in	
conjunction	with	tumor	vaccines	are	required	to	determine	if	MAIT	cells	have	similar	adjuvant-like	
activity	to	type	I	NKT	cells.	Based	on	the	promising	results	using	in	vitro	expanded	CAR-NKT	cells	in	
humanised	mouse	models,	 similar	 studies	using	CAR-MAIT	cells,	CAR-γδ	 T	and	CAR	MHC	class	 Ib-
restricted	T	cells	are	also	worthy	of	investigation.		
	
Checkpoint	 blockade	 therapy	 using	 anti-PD1	 and	 anti-CTLA-4	 based	 drugs	 to	 inhibit	 tumor-
mediated	immunosuppression	is	proving	to	be	a	very	powerful	approach	to	treating	some	types	of	
cancer	 (Melero	et	al.,	2015).	While	 this	 therapy	 is	usually	assumed	 to	act	primarily	via	enhanced	
CD8+	T	cell-mediated	tumor	destruction,	the	potential	role	that	unconventional	T	cells	play	should	
be	 considered,	 given	 that	 they	also	express	 the	 inhibitory	 receptors	 such	as	PD1	upon	activation	
and	 that	 blockade	 of	 these	 receptors	 can	 enhance	 their	 cytokine	 production	 and	 anti-tumor	
capacity	(Chang	et	al.,	2008b;	Durgan	et	al.,	2011;	Iwasaki	et	al.,	2011;	Jiang	et	al.,	2014).	Moreover,	
as	one	of	the	key	resistance	genes	associated	with	checkpoint	blockade	therapy	is	β2M	(Zaretsky	et	



















Unconventional	 T	 cells,	 divided	 into	 groups	 based	 on	 their	 restriction	 elements.	 5-OP-RU,	 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil;	 6-FP,	 6-formylpterin;	 Ag,	 antigen;	 α-GalCer,	 α-
galactosylceramide;	GEM,	germline	encoded	mycolyl	lipid-reactive;	mLPA,	methyl	lysophosphatidic	




Top	 left	 panel.	 A	 cartoon	 of	 a	 type	 I	 NKT	 cell	 recognising	 α-GalCer	 presented	 by	 a	 CD1d+	 Ag	
presenting	 cell.	 The	 ternary	 crystal	 structure	 of	 the	 TCR-CD1d-α-GalCer	 complex	 is	 shown	 in	 the	
inset.	 Top	 right	 panel.	 A	 sample	 of	 synthetic	 lipid	 analogues	 that	 have	 the	 ability	 to	 provide	
enhanced	and/or	Th1-biased	type	I	NKT	cell	responses.		Bottom	panel.	Examples	of	tumor-derived	
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